U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888505) titled 'Dapagliflozin for Prevention of Chemotherapy-Induced Cardiotoxicity: a Randomized Controlled Trial' on March 03.
Brief Summary: Brief Summary
Background & Rationale Anthracyclines, such as doxorubicin, and trastuzumab (Herceptin) are widely used in cancer treatment but are associated with cardiotoxicity, which can lead to left ventricular dysfunction, heart failure, and long-term cardiovascular complications. Anthracycline-induced cardiotoxicity is primarily dose-dependent and often irreversible, resulting from oxidative stress, mitochondrial damage, and apoptosis of cardiomyocytes. In contrast, trastuzumab-induced cardiotoxicity ...